What should you know about IDH1 immunohistochemistry?

A pathologist applies an antibody-based stain to prepared tissue, usually from a [Biopsy] or surgical sample. The stain attaches to its target and is examined under a microscope. A positive-looking stain can support the presence of the targeted IDH1 change; a negative result means that change was not detected by that stain. The report may recommend another molecular method when the appearance is unclear or a different IDH change is suspected.

This test does not examine the whole body and does not diagnose a tumour from symptoms. Its meaning depends on the tissue diagnosis, scan findings, tumour grade, and other laboratory results.

Ask whether the stain assessed the common IDH1 change or whether broader testing was performed. Find out whether the sample contained enough tumour and whether the result matches the microscopic diagnosis. The result can help classify a glioma and guide discussion of monitoring, surgery, radiotherapy, or medicines, but treatment is not chosen from the stain alone.

Request the pathology wording in writing and ask who will combine it with imaging and clinical information. If the sample was taken recently, follow the procedure team’s instructions for wound care and symptom reporting.

The stain itself does not cause symptoms, but seek urgent help for a first seizure, sudden weakness, new speech difficulty, severe confusion, collapse, or rapidly worsening headache with repeated vomiting. After a biopsy or operation, contact the hospital urgently for fever, worsening wound redness or discharge, severe drowsiness, or a new neurological change.

Which IDH1 alteration does the stain detect? Was the result positive, negative, or technically limited? Is confirmatory molecular testing needed? How much tumour was present in the sample? How does this result fit the scan and full pathology report? Does it change the next treatment discussion?